The conventional wisdom for CPG startups was to be "asset-light" and use co-packers. However, owning the supply chain provides crucial control over quality, production schedules, and cash flow, preventing startups from being pushed aside by a co-packer's larger clients. This control is now a key diligence point.

Instead of starting in a kitchen, CPG entrepreneur Emma Hernan bought a manufacturing facility first. This generated revenue by co-packing for other brands, secured her own supply chain, and created multiple income streams from a single asset before her product even launched.

Having not raised capital since 2021, The Gist operates by using revenue from its existing products to fund its next strategic bets. This forces a disciplined approach, prioritizing new initiatives with a clear path to monetization to fuel future growth.

Early on, Spin Master's founders needed manufacturing and packaging help. Instead of giving away precious company equity, they offered family members a 5% profit share on that specific product. This is a tactical way to secure human capital without long-term dilution.

For hardware startups constrained by working capital, building deep trust with a manufacturer can be a form of financing. Belkin's founder convinced his manufacturer to produce and hold inventory on their own books, allowing Belkin to pull stock as needed without having to fund it all upfront.

By manufacturing in-house, Buy Rosie Jane maintained profitability and control over its cash flow. This vertical integration was the key that allowed the bootstrapped company to handle large purchase orders from major retailers like Anthropologie and Sephora without needing outside investment.

Instead of raising venture capital, the company used its profitable B2B channel selling to boutiques as a financial engine. The consistent cash flow from wholesale partners funded their early, more speculative investments in direct-to-consumer digital advertising.

By partnering with a local manufacturer willing to align payment cycles with retail payouts, Candier bypassed the cash flow trap that sinks many CPG startups. This strategic partnership was crucial for funding large inventory orders for major retailers like Ulta and Whole Foods without taking on debt or outside investment.

To manage the long, costly timeline of therapeutic development, a biotech can create revenue-generating subsidiaries. One can offer its platform as a service (like a CDMO), while another sells lower-regulation products like cosmetic ingredients for faster market entry. This provides crucial cash flow to sustain the core drug pipeline.